Want to see GB:CIZ full AI Analyst Report?
Top Page
Cizzle Biotechnology Holdings PLC
(LSE:CIZ)
Select Model
Select Model
Rating:47Neutral
Price Target:
2.50 p
▲(61.29% Upside)
Action:Reiterated
Date:06/18/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn, and equity turning negative in 2025). Technical indicators provide some support via longer-term uptrend and positive MACD, but valuation remains constrained by continued losses and no dividend data.
Positive Factors
Focused lung cancer diagnostics
Cizzle's product strategy concentrates on blood-based early lung cancer diagnostics, a clear clinical target with structural demand. A focused R&D agenda and validation path support durable differentiation if clinical utility and regulatory acceptance are achieved, aiding long-term commercial potential.
Negative Factors
Pre-revenue with persistent losses
Being pre-revenue and repeatedly reporting negative operating and free cash flow means the business cannot self-fund development. Structural reliance on outside capital increases dilution and execution risk, lengthens time to commercialization, and makes long-term progress contingent on successful raises or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused lung cancer diagnostics
Cizzle's product strategy concentrates on blood-based early lung cancer diagnostics, a clear clinical target with structural demand. A focused R&D agenda and validation path support durable differentiation if clinical utility and regulatory acceptance are achieved, aiding long-term commercial potential.
Read all positive factors
Cizzle Biotechnology Holdings PLC (CIZ) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£10.20M
Dividend YieldN/A
Average Volume (3M)1.23M
Price to Earnings (P/E)―
Beta (1Y)-0.63
Revenue GrowthN/A
EPS Growth69.64%
CountryUK
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding424,963,200
10 Day Avg. Volume655,017
30 Day Avg. Volume1,232,506
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-18.07
Price to Sales (P/S)0.00
P/FCF Ratio-12.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cizzle Biotechnology Holdings PLC Business Overview & Revenue Model
Company Description
Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzl...
How the Company Makes Money
null...
Cizzle Biotechnology Holdings PLC Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -753.00K | -878.00K | -976.00K | -963.00K | -3.96M |
| Net Income | -691.00K | -2.17K | -1.72K | -910.00K | -3.92M |
Balance Sheet | |||||
| Total Assets | 245.00K | 492.00K | 1.69M | 2.79M | 1.16M |
| Cash, Cash Equivalents and Short-Term Investments | 116.00K | 387.00K | 1.56M | 478.00K | 875.00K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 585.00K | 410.00K | 186.00K | 145.00K | 218.00K |
| Stockholders Equity | -340.00K | 82.00K | 1.51M | 2.64M | 937.00K |
Cash Flow | |||||
| Free Cash Flow | -498.00K | -358.00K | -639.00K | -872.00K | -1.21M |
| Operating Cash Flow | -496.00K | -358.00K | -639.00K | -872.00K | -1.01M |
| Investing Cash Flow | -2.00K | 0.00 | 0.00 | -120.00K | -154.00K |
| Financing Cash Flow | 249.00K | 579.00K | 305.00K | 595.00K | 2.03M |
Cizzle Biotechnology Holdings PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £4.62M | -4.30 | -53.79% | ― | ― | 85.56% | |
49 Neutral | £6.56M | -1.68 | -2.42% | ― | 34.02% | -93.85% | |
47 Neutral | £10.20M | -14.12 | -433.59% | ― | ― | 69.64% | |
44 Neutral | £5.22M | 6.67 | -153.80% | ― | ― | 93.02% | |
42 Neutral | £2.18M | -0.18 | ― | ― | -36.97% | 71.72% | |
41 Neutral | £2.92M | -0.19 | -115.97% | ― | -87.82% | -746.51% |
* Healthcare Sector Average
GB:CIZ
Cizzle Biotechnology Holdings PLC
2.40
0.85
54.84%
GB:TCF
Evgen Pharma
0.22
-0.05
-17.31%
GB:FUM
Futura Medical
0.50
-7.50
-93.73%
GB:NFX
Nuformix Plc
0.20
0.11
122.22%
GB:OPTI
OptiBiotix Health
6.35
-5.65
-47.08%
GB:VAL
ValiRx plc
0.17
-0.41
-71.30%
Cizzle Biotechnology Holdings PLC Corporate Events
Financial DisclosuresPrivate Placements and FinancingShareholder Meetings
Cizzle Biotechnology shareholders back all AGM resolutions, expand board authorities
Positive
Jun 16, 2026
Cizzle Biotechnology Holdings reported that all resolutions at its latest annual general meeting were passed by a show of hands, with proxy votes showing overwhelming support across all motions. Shareholders approved the 2025 accounts and remunera...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Cizzle wins U.S. CLIA approval for CIZ1B early lung cancer blood test
Positive
Jun 16, 2026
Cizzle Biotechnology has secured CLIA accreditation in the U.S. for its proprietary CIZ1B biomarker blood test, enabling clinical use at OmniHealth Diagnostics in Dallas and allowing licensed U.S. healthcare providers to order the test. The lab-de...
Business Operations and StrategyProduct-Related Announcements
Cizzle Biotechnology Gains Key U.S. Patent for CIZ1B Lung Cancer Test
Positive
Jun 12, 2026
Cizzle Biotechnology has secured a key U.S. patent covering its core methods for measuring the CIZ1B lung cancer biomarker, adding to existing protection in Canada and Europe. The patent supports its North American licensee, Cizzle Bio Inc, as it ...
Business Operations and StrategyShareholder Meetings
Cizzle Biotechnology Sets June Date for AGM as It Advances Lung Cancer Test Commercialisation
Positive
May 21, 2026
Cizzle Biotechnology Holdings plc has notified shareholders that its Annual General Meeting will take place on 16 June 2026 at the offices of Shakespeare Martineau LLP in London, with the formal notice already posted and available on the company&#...
Business Operations and StrategyExecutive/Board Changes
Cizzle Ties Executive Incentives to Lung Cancer Test Milestones Amid Ongoing Salary Waivers
Positive
May 7, 2026
Cizzle Biotechnology Holdings has introduced a new performance-based management incentive plan and conditionally granted share options to directors, subject to shareholder approval, in lieu of salary increases that have been waived since its 2021 ...
Private Placements and FinancingRegulatory Filings and Compliance
Cizzle Biotechnology Converts £400,000 of Loan Notes Into New Equity
Positive
May 6, 2026
Cizzle Biotechnology has received a notice from investor Frazer Lang to convert £400,000 of existing convertible loan notes into 28,571,429 new ordinary shares at 1.4 pence per share, strengthening its equity base and reducing outstanding deb...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Cizzle Biotechnology Publishes 2025 Annual Report and Financial Statements
Neutral
Apr 30, 2026
Cizzle Biotechnology Holdings has published its Annual Report and Financial Statements for the year ended 31 December 2025. The document, detailing the company’s financial performance and activities over the period, is now available online t...
Business Operations and StrategyPrivate Placements and Financing
Cizzle Biotechnology Secures £250,000 Convertible Funding To Back Lung Cancer Test Rollout
Positive
Apr 2, 2026
Cizzle Biotechnology has arranged a new unsecured funding facility of up to £250,000 in convertible loan notes with existing investor Frazer Lang, extending previously agreed note programmes that now total £400,000 already drawn. The new...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.